RECRUITING

Biological Effects of Quercetin in COPD Phase II

Talk to us

Conditions

Chronic Obstructive Pulmonary DiseaseEmphysemaChronic Bronchitis With Airway ObstructionCOPD, quercetin, polyphenol, mucus, airway obstruction

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study determines whether quercetin supplementation reduces the inflammation and oxidative stress markers in patients with chronic obstructive pulmonary disease. It is small study with 8 subjects receiving quercetin 1000 mg/day, 8 patients receiving 500 mg/day and 4 subjects receive placebo.

Official Title

Effects of Quercetin on the Oxidative Stress and Inflammatory Markers in COPD Phase II

Quick Facts

Study Start:2023-11-01
Study Completion:2025-07-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06003270

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:40 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Subjects with COPD, 40 - 80 yrs of age
  2. * Post-bronchodilator forced expiratory volume (FEV)1/forced vital capacity (FVC) ratio 0.7, FEV1% predicted between 40 to 70
  3. * Both active and ex-smokers with at least 10 pack-years history of smoking
  4. * COPD patients taking H2 antagonists, loperamide or loratadine and willing to stop during the study period
  1. * Known allergy/sensitivity to quercetin
  2. * Subjects with primary current diagnosis of asthma
  3. * Upper respiratory tract infection within two weeks of the screening visit
  4. * Acute bacterial infection requiring antibiotics within two weeks of screening
  5. * Emergency treatment or hospitalization within one month of screening for any reasons
  6. * Unwillingness to stop flavonoid supplementation
  7. * Dietary intake exceeding or averaging 150 mg quercetin daily as assessed by Bioflavonoid Food and Supplement Screener
  8. * Daily warfarin or cyclosporine (Neoral, Sandimmune)
  9. * Subjects taking H2 antagonists (cimetidine, ranitidine), loperamide (Imodium) or loratadine and not willing to stop during study period
  10. * Lung cancer history or undergoing chemo- or radiation therapy
  11. * Inflammatory bowel disease
  12. * Women of child-bearing age and unwilling to take pregnancy test
  13. * Child-bearing age, who are unwilling to use adequate contraception or abstain during the course of the study.
  14. * Pregnant or lactating mothers

Contacts and Locations

Study Contact

Umadevi Sajjan
CONTACT
2157077139
uma.sajjan@temple.edu

Principal Investigator

Nathaniel Marchetti
PRINCIPAL_INVESTIGATOR
Temple University

Study Locations (Sites)

Nathaniel Marchetti
Philadelphia, Pennsylvania, 19140
United States

Collaborators and Investigators

Sponsor: Temple University

  • Nathaniel Marchetti, PRINCIPAL_INVESTIGATOR, Temple University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-11-01
Study Completion Date2025-07-31

Study Record Updates

Study Start Date2023-11-01
Study Completion Date2025-07-31

Terms related to this study

Keywords Provided by Researchers

  • COPD, quercetin, polyphenol, mucus, airway obstruction

Additional Relevant MeSH Terms

  • Chronic Obstructive Pulmonary Disease
  • Emphysema
  • Chronic Bronchitis With Airway Obstruction